2025

1. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

   Blood Cancer Journal, Vol. 15, Núm. 1

2. Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care

   Frontiers in Immunology, Vol. 15

3. Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study

   British Journal of Haematology, Vol. 207, Núm. 4, pp. 1504-1516

4. Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation

   Cancers, Vol. 17, Núm. 19